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Abstract
Purpose: Radical changes in both expression and glycosylation pattern of transmembrane mucins have been observed in
various malignancies. We and others have shown that MUC1 and MUC4, two transmembrane mucins, play a sentinel role in
cell signaling events that drive several epithelial malignancies. In the present study, we investigated the expression profile
of MUC1 and MUC4 in the non-neoplastic bladder urothelium, in various malignant neoplasms of bladder and in bladder
carcinoma cell lines.
Material and Methods: Immunohistochemistry was performed on tissue sections from the urinary bladder biopsies,
resection samples and tissue microarrays (TMAs) with monoclonal antibodies specific for MUC1 and MUC4. We also
investigated their expression in bladder carcinoma cell lines by RT-PCR and immunoblotting.
Results: MUC1 is expressed on the apical surface or in umbrella cells of the normal non-neoplastic bladder urothelium.
Strong expression of MUC1 was also observed in urothelial carcinoma (UC). MUC1 staining increased from normal
urothelium (n = 27, 0.3560.12) to urothelial carcinoma (UC, n = 323, H-score, 2.460.22, p#0.0001). In contrast to MUC1,
MUC4 was expressed in all the layers of non-neoplastic bladder urothelium (n = 14, 2.560.28), both in the cell membrane
and cytoplasm. In comparison to non-neoplastic urothelium, the loss of MUC4 expression was observed during urothelial
carcinoma (n = 211, 0.5660.06). However, re-expression of MUC4 was observed in a subset of metastatic cases of urothelial
carcinoma (mean H-score 0.73460.9).
Conclusion: The expression of MUC1 is increased while that of MUC4 decreased in UC compared to the normal non-
neoplastic urothelium. Expression of both MUC1 and MUC4, however, are significantly higher in urothelial carcinoma
metastatic cases compared to localized UC. These results suggest differential expression of MUC1 and MUC4 during
development and progression of bladder carcinoma.
Citation: Kaur S, Momi N, Chakraborty S, Wagner DG, Horn AJ, et al. (2014) Altered Expression of Transmembrane Mucins, MUC1 and MUC4, in Bladder Cancer:
Pathological Implications in Diagnosis. PLoS ONE 9(3): e92742. doi:10.1371/journal.pone.0092742
Editor: Rajvir Dahiya, UCSF/VA Medical Center, United States of America
Received January 13, 2014; Accepted February 25, 2014; Published March 26, 2014
Copyright: ß 2014 Kaur et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the grants from the National Institutes of Health (RO1 CA 138791, U54 CA163120, UO1 CA111294, and P50 CA127297). The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: slele@unmc.edu (SML); sbatra@unmc.edu (SKB)
Introduction
Bladder cancer (BCa) is the fifth common malignancy in the
United States accounting for nearly 72,570 new cases and 15,210
cancer-related deaths during 2013 [1]. The urothelial carcinoma
(UC) is the most common histologic type of BCa that accounts for
.90% of the newly diagnosed cases. UCs at the time of diagnosis
range from superficial low-grade papillary lesions (associated with
better prognosis) to highly invasive malignant carcinomas (highly
aggressive with a low survival). Approximately, 70–80% of newly
diagnosed UCs are ‘‘non–muscle invasive’’ wherein the disease is
confined to the bladder mucosa or lamina propria (stage Ta/T1
according to TNM classification) [2]. About 10%–30% of these
tumors advance to ‘‘muscle-invasive disease’’ (‘‘high grade’’ UC)
(stage T2/T3) [2]. Low-grade papillary cancers are generally non-
invasive (only ,15% invade the bladder wall) and thus amenable
to surgical resection. However, the cases of high grade invasive
carcinoma are associated with high probability of metastasis and
mortality [3,4]. Cytology and cystoscopy with tissue biopsy remain
the most accurate methods available to detect BCa till date.
Cytology is highly specific for high-grade urothelial carcinoma but
not for low-grade urothelial carcinoma.
In recent years, aberrant changes in the expression and
glycosylation of mucins have been reported in inflammatory,
premalignant and malignant conditions [5–10]. Mucins are
glycoproteins that are characterized by the presence of high
degree of O- and N-glycosylation together with highly repetitive
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short stretches of amino acid residues (termed as ‘‘tandem
repeats’’) [9]. These are broadly divided into two categories
namely membrane bound mucins and secreted/gel forming
mucins. Importantly, MUC1 and MUC4 represent the well
characterized trans-membrane mucins playing important roles in
cellular physiology. By virtue of their structure and biochemical
composition these mucins participates in lubrication and hydration
of cell surfaces, protection from microorganisms (bacteria and
viruses) and degradative enzymes [11]. Variation in the expression
and glycosylation pattern of MUC1 and MUC4 has been observed
in several epithelial malignancies including pancreatic, breast,
colon, prostate and lung cancer [7,9,12,13]. They have been
shown to play a critical role in tumor growth, intracellular and
extracellular signaling, tumor–stromal interactions, metastasis, and
resistance to chemotherapeutic agents and in immune surveillance
[7,11,12,14]. The availability of highly specific reagents (e.g.
monoclonal antibodies), some capable of recognizing altered
glycoforms has made mucins attractive targets for the early
diagnosis of epithelial malignancies. Altered expression and
localization pattern of MUC1 have been observed during
progression of malignant neoplasms of bladder [15–18], however
to date there is a dearth of information on the status of MUC4.
Considering their protective and lubricating roles, it is important
to assess their functions in the healthy bladder and the alteration in
their expression during the development and progression of
urothelial carcinoma.
In the present study, we examined the expression patterns of
MUC1 and MUC4 in non-neoplastic bladder urothelium and
malignant neoplasms of bladder tissues on tissue microarrays
(TMA) and tissue sections from the urinary bladder biopsies and
resected samples. Further, the correlation between expression of
these mucins and tumor grade (grades 1–4) was examined to
define the diagnostic and physiological significance of TM mucins
during pathogenesis of UC.
Materials and Methods
Tumor Cell Lines and Tissue Specimens
Archived formalin fixed BCa tissue samples were obtained
University of Nebraska Medical Center tissue bank. The review
board found this study, with its de-identified database, to be
exempt from institutional review board review. Bladder TMA
were purchased from US Biomax for MUC1 staining
(cat#BL802), Accumax for MUC4 (cat#A215II) and Bladder
TMA (2004) (a kind gift from Dr. Henry Frierson from University
of Virginia Charlottesville VA). IHC staining was performed using
mAb HMFG2 (anti-MUC1 antibody, a kind gift from Dr.
Gendler, Mayo Clinics), and mAb8G7 (anti-MUC4 antibody,
generated against tandem repeat peptide,
STGDTTPLPVTDTSSV in our laboratory and reactive with
both native protein and peptide) [19]. Bladder carcinoma cell lines
[T24 and HT1376, (derived from bladder transitional cell
carcinoma), TCCSUP (derived from an anaplatic transitional cell
carcinoma) SCaBER (derived from bladder squamous cell
carcinoma) were maintained in the American Type culture
Collection (ATCC) specified culture media supplemented with
10% FBS and 1% penicillin-streptomycin (Gibco BRL, Grand
Island, NY). Growth media was changed on alternate days and the
cells were trypsinized at 70% confluency.
Immunohistochemistry (IHC)
For analyzing MUC1 and MUC4 expression in malignant
neoplasms of bladder, IHC was performed as described previously
on TMA and tissue sections of samples from the urinary bladder
[7]. Biopsy and resection samples of urothelial carcinoma were
reviewed by the pathologists (Drs. S Lele, AH Horn, and DG
Wagner at UNMC) to confirm the diagnoses and also select
representative blocks for immunohistochemical analyses. For tissue
IHC, 4 mm thick sections were cut from paraffin-embedded tissue
blocks using tissue microtome and were adhered on to the charged
glass slides. Bladder TMA and tissue sections were incubated
overnight at 56uC followed by deparaffinization using repeated
washes of xylene (5 min each) followed by rehydration of tissues
with graded alcohol. After rehydration, tissues were incubated
with methanolic solution of 3% H2O2 for quenching of
endogenous peroxidase activity. Heat induced antigen retrieval
was performed heating the sample in 0.01M citrate (pH 6.0, 95uC)
buffer for 15 min in microwave oven. Following antigen retrieval,
the sections were blocked with horse serum (ImmPRESS
Universal antibody kit; Vector Laboratories) for 3 hrs at room
temperature. The slides were further incubated with anti-MUC1
(HMFG2 at 1:5 dilution of enriched supernatant in PBS), MUC4
antibody 8G7 (1:2000 dilution of a 1.8mg/ml stock in PBS) [20]
overnight at 4uC. After four washes with PBS-T (PBS containing
0.05% Tween 20), the sections were incubated with anti-mouse
secondary antibody (ImmPRESS Universal antibody kit; Vector
Laboratories) for 30 min. and subsequently, the color was
developed by adding 3,39-diaminobenzidine solution (DAB
substrate kit; Vector Laboratories). Reddish brown precipitate
indicated positive immuno-reactivity. The slides were counter-
stained with Gill’s haematoxylin (Vector Laboratories), dehydrated
in graded ethanol followed by xylene and mounted with Vecta-
mount mounting medium (Vector Laboratories). All slides were
analyzed using a Nikon Eclipse E400 Microscope (Nikon
Corporation, Tokyo, Japan).
Each tissue core was evaluated by the uropathologists at UNMC
to assess the presence of tumor and scoring of staining. Briefly,
each spot on the tissue array was graded based on the intensity of
staining on a scale of 0 to 3 (0-no staining, 1-weak staining, 2-
intermediate staining, and 3-strong staining). The percentage of
positive cells with a given intensity for each sample was determined
by the pathologists. The H-score [range: 0 (no staining in any cell)
to 3 (all cells staining with the highest (3) intensity] was calculated
as the summation of the product of staining intensity (range: 0–3)
and proportion of cells staining (range: 0–1; 0-no cell stained and
1–100% cell stained). As per H-score focal reactivity corresponds
to H score of #0.1, mild reactivity (H score .0.1 but less than or
equal to 1.0), moderate reactivity (H score .1.0 but #2.0) and
intense reactivity (H score .2.0). In case of tissue biopsies due to
limited number each tissue type (benign, carcinoma in-situ and
carcinoma) present on the slide was scored on the intensity score
only. In metastatic cases, sections were scored for H-scoring
similar to tissue spots.
Statistical Analyses
Data was analyzed using Medcalc for Windows version 9.6.4.0
software. For the purpose of analysis, each spot was considered as
an individual sample. Intensity of mucin expression were
considered as continuous variables, however the type of pathology
[UC, squamous cell carcinoma (SCC), adenocarcinoma or
papillary carcinoma], grade of cancer were considered as
categorical variables. A p value of ,0.05 was considered
significant.
Isolation of Total RNA and Reverse Transcriptase-
Polymerase Chain Reaction
Cellular RNA from the cultured cells was extracted by RNeasy
kit according to manufacturer instructions (Qiagen, Hilden,
Transmembrane Mucins Expression in Bladder Pathogenesis
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Germany). Total RNA was quantified using an ultraviolet
spectrophotometer (Peqlab ND-1000; Peqlab, Erlangen, Ger-
many) and the quality and integrity of samples were assessed on a
1.5% agarose gel. 2 mg of total RNA from each BCa cell line was
reverse transcribed using the first-strand cDNA synthesis kit
(Perkin Elmer, Branchburg, NJ) according to the manufacturer’s
instructions. The quantitative real time PCR was performed for
MUC1, MUC4, and b-actin using following primer pairs: MUC1
(forward primer 59-GAACTACGGGCAGCTGGACATC9-39
and reverse primer 59-GCTCTCTGGGCCAGTCCTCCTG-
39), MUC4 (forward primer 59-CGCGGTGG
TGGAGGCGTTCTT-39 and reverse primer 59-GAA-
GAATCCTGACAGCCTTCA-39), and b-actin forward primer
(59-TGGACATCCGCAAAGACCTG-39) and reverse primer (59-
CCGATCCACA CGGAGTACTT-39) (IDT Cor- alville, IA,
USA).
Western-Blot Analysis
Total protein was extracted from BCa cell lines, resolved and
analyzed by immunoblotting according to standard protocol. In
brief, cells were washed twice with cold-PBS, scraped in RIPA
buffer (100 mM Tris, 5 mM EDTA, 5% NP40, pH-8.0) contain-
ing protease inhibitors cocktail (Roche diagnostics, Mannheim,
Germany) and allowed to lyse for at least 30 min on ice with
intermittent vortexing. Cells were subjected to further lysis by one
freeze-thaw cycle and centrifuged at 14,000g for 30 min at 4uC.
Supernatants were carefully removed and protein concentrations
were determined by Bio-Rad-DC protein estimation kit. For
mucin immunoblotting, electrophoresis was performed on 2%
SDS-agarose gel using equal amounts of protein samples under
reducing conditions. For b-actin, SDS–PAGE (10%) was run
under similar conditions. Proteins were transferred to the PVDF
membranes and probed with anti-MUC1 (1:5 diluted
mAbHMFG2 supernatant in PBS) and MUC4 (1:1,000 dilution
of mAb8G7) antibodies. After incubation with mouse horseradish
peroxidase-conjugated secondary antibodies (Amersham Biosci-
ences Buckinghamshire, UK), signal was detected with an
electrochemiluminescence reagent kit (Amersham Pharmacia,
Piscataway, NJ).
Results
In this study, we explored the expression profile of transmem-
brane mucins (MUC1 and MUC4) in urothelial carcinoma tissue
sections and three tissue TMAs. Further, expression levels of these
mucins were assessed in bladder carcinoma cell lines.
MUC1 Expression Analyses during Malignant Neoplasms
of Bladder
MUC1 expression in the non-neoplastic bladder
urothelium. Majority of the non-neoplastic bladder tissues
spots from TMA (16/27 or 59%) were negative for MUC1
expression (H score = 0). Minor focal staining was observed in
some cases 4/27 (15%). In the remaining spots, mild positivity was
observed (7/27 mean H-score 0.5860.29 on a scale of 0–3)
(Fig. 1A). Overall, mean H-score of all the cases together was
Figure 1. Expression of MUC1 in non-neoplastic bladder urothelium, non-invasive papillary urothelial carcinoma, urothelial
carcinoma in situ and invasive high grade urothelial carcinoma. Bladder tumor tissue sections or spots were probed with anti-MUC1 mAb
(HMFG2) after non-specific blocking with horse serum. All sections were examined under microscope and the immunoreactivity was evaluated by
reddish brown staining. Representative photomicrographs are shown for MUC1 stained non-neoplastic bladder urothelium (A&B), low-grade papillary
carcinoma (C), bladder carcinoma in situ (D), and high grade invasive cancer (E&F). In normal bladder urothelium, MUC1 expression was restricted to
umbrella cells (shown by arrowhead in panel A and the magnified inset) in majority of samples. In some samples, a sheath of MUC1 mucin was
observed over urothelium (arrow in 1B). In low-grade papillary carcinoma, intense staining of MUC1 was observed on the luminal surface of the
urothelium and lower intensity of staining was observed in the other layers of urothelium (C). In urothelial carcinoma in situ, MUC1 expression was
observed in all the layers of urothelium, however, staining was comparatively stronger in cells closer to the luminal border (D). In invasive high grade
urothelial carcinoma, MUC1 staining was observed in cells invading singly (E) or as small groups within the lamina propria (F).
doi:10.1371/journal.pone.0092742.g001
Transmembrane Mucins Expression in Bladder Pathogenesis
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found to be 0.1560.1 (Table 1). In majority of the cases, intense
MUC1 staining was restricted to umbrella cells with weak staining
in remainder cells of the urothelium (Fig. 1A, arrowhead).
However in few cases, an intense MUC1 staining (4/27 or 15%)
was observed superficial layer of the urothelium (Fig. 1B,
depicted by arrow). In general, staining was highly intense in
the superficial umbrella cells than in the other layers/cells of the
urothelium. A similar finding was noted for tissue sections
collected at UNMC which revealed moderate to intense staining
for MUC1 (N=3, mean intensity 1.760.58, mean H-score
1.760.58) that was restricted to superficial layer or umbrella cells.
MUC1 expression in non-invasive papillary urothelial
carcinoma and urothelial Carcinoma In Situ
(CIS). Papillary cancers are generally non-invasive (only ,
15% invade the bladder wall) and thus amenable to surgical
resection. For MUC1, papillary carcinoma cases were restricted to
tissue sections alone, as no tissue spot in TMA corresponded to
invasive or non-invasive papillary carcinoma. Moderate to intense
MUC1 staining was observed in both low and high grade papillary
urothelial carcinoma from tissue sections (mean intensity 2.960.1
and mean H-score 2.160.83 on a scale of 0–3, Fig. 1C). Intense
staining of MUC1 was observed on the luminal surface of the
uroepithelium in low grade papillary urothelial carcinoma.
Staining intensity and percentage positivity increased from cells
in basal layers to apical layers of the uroepithelium (Fig. 1C,
depicted by arrow). Furthermore, surface layer cells showed
more intense staining as compared to the cells underneath
uroepithelial layer, demonstrating a non-uniform cell to cell
staining pattern (Fig. 1C). In case of carcinoma in situ, intense
MUC1 staining (mean intensity 2.960.1 and mean H-score
2.4860.74) was observed (N= 10) in the tissue sections (Fig. 1D).
MUC1 expression in primary and metastatic urothelial
carcinoma. In urothelial carcinoma cases, MUC1 staining
varied from no reactivity (N= 38 or 12%), focal reactivity (N= 12
or 4%, mean H-score 0.05760.01) to moderate (N= 147 or 46%,
mean H-score 1.0260.05) and intense immunoreactivity (N= 117
or 37%, mean H-score of 2.8660.02) (Fig. 1E and 1 F). In
invasive cases, MUC1 staining was observed in foci (single or nest
of cells) present within the papillary core or in the lamina propria
(Fig. 1E and 1F), the distribution of MUC1 being both
membranous and cytoplasmic.
MUC1 expression was observed in 66% (8/12) of metastases
from a primary UC to various locations i.e. abdominal wall, back,
bone, brain and lymph nodes (Fig. 2E and F). In case of
metastatic tissue sections (n = 28), absolute expression of MUC1
was observed in all metastatic cases with mean H-score of
1.9160.15 and mean intensity of 2.7260.45. In accordance with
these results, no MUC1 expression was observed in normal lymph
node area while metastatic cells within the lymph node have
positive reactivity (Fig. 2E). The observed MUC1 expression can
be categorized into three different patterns luminal membrane
staining (in the umbrella cell layer) only, luminal plus cytoplasmic
staining (in intermediate and basal layers), or staining of only
isolated cells or cell groups.
As seen in Table 2, significant difference in H-score of MUC1
staining was observed from grade 1 (0.5160.1) to grade 2 tumors
(1.6260.155). Further H-score for MUC1 staining increased from
grade 3 to grade 4 tumors.
MUC1 expression in Squamous Cell Carcinoma (SCC),
adenocarcinoma and mucinous adenocarcinoma of the
bladder. Moderate to intense staining was observed in SCC
(N=33, 65% of cases) with the mean H-score 2.3360.16
(Fig. 2A), while others showed only mild positivity for MUC1
(N=18 or 35%, mean H-score 0.6660.11, mean intensity
1.360.11). Moderate staining for MUC1 was observed in keratin
pearls which are distinctive feature of grade 1 squamous cell
carcinoma (Fig. 2B, depicted by arrow). There was no
significant difference in staining intensity between grade 2 (N= 6,
mean H-score 260.3) and grade 3 SCC (N=12, mean H-score
3.060.7). Of the 12 adenocarcinomas spots which were examined,
7 showed weak staining of MUC1 (Fig. 2C) while in others
expression was completely absent. Majority of tissue spots from
mucinous adenocarcinoma were mildly positive for MUC1 (mean
H-score, 0.6260.14) (Fig. 2D).
MUC4 Expression Analyses during Malignant Neoplasm
of Bladder
MUC4 expression in the non-neoplastic bladder
urothelium. When analyzed in normal tissues (N= 14), high
expression of MUC4 was observed in urothelium of the non-
neoplastic bladder (Fig. 3A, mean intensity 2.5460.21 and mean
H-score 2.5460.21) (Table 3). The expression of MUC4 (in the
normal bladder urothelium) was observed both in the membrane
and cytoplasm of epithelium cells with stronger expression on cell
membranes than cytoplasm. However, in contrast to MUC1, the
staining for MUC4 was uniform through all the layers of
urothelium (Fig. 3A). Interestingly, a strong expression of
MUC4 was observed even in invaginated aggregates of urothelial
cells known as ‘‘von Brunn’s nests’’ (Fig. 3B, depicted by
arrow).
MUC4 expression in non-invasive and invasive papillary
urothelial carcinoma and urothelial Carcinoma In Situ
(CIS). Although limited cases (N= 6) of non-invasive papillary
carcinoma were present in tissue spots, majority of them were
completely negative (N= 4, intensity-score 0) while other have
partial positivity (N= 2, mean intensity-score 2.5). Invasive
papillary carcinoma (N=2) showed complete loss of MUC4
expression (Intensity-score = 0). Further, complete loss of MUC4
expression was observed in both non-invasive (Fig. 3C) and
invasive cases of papillary carcinoma (N=10, mean intensity
0.860.41; mean H-score 0.3160.39). MUC4 expression was
significantly downregulated in CIS from TMA (N=4, mean H-
score 0, table 3) as well as in case of tissue sections (N= 10; mean
intensity 0.360.1; p = 0.02 and mean H-score 0.1260.06)
compared to the non-neoplastic urothelium (Fig. 3D). Overall,
loss of MUC4 expression was observed during invasive and non-
invasive papillary carcinoma.
MUC4 expression in invasive urothelial carcinoma and
metastasis. In majority of the cases, focal expression of MUC4
was observed in urothelial carcinoma (N= 122 or 58%, mean H-
score, mean intensity 0) whereas other cases showed mild positivity
(N= 89 or 42% cases, mean H-score 0.6860.14, mean intensity
0.9160.19). Overall, the loss of MUC4 expression was observed in
both low and high grade invasive urothelial carcinoma (Fig. 3E
and 3F). MUC4 expression was significantly down-regulated in
carcinoma cells compared to the non-neoplastic urothelium (mean
H-score in the non-neoplastic bladder urothelium and UC being
2.5460.21 [p,0.0001], and 0.4760.05 respectively) (data from
TMA). Interestingly, in comparison to urothelial carcinoma that
lacks the expression of MUC4, higher percentage of metastatic
cases were found to be positive for MUC4. Among all (N= 28)
metastatic cases, 57% cases (N=16) demonstrated weak to mild
MUC4 staining (mean H-score 1.2760.27) (Fig. 4D–F) while
none to focal expression was observed in 43% of cases (N= 12;
mean intensity = 0 and mean H-score 0.02560.02). Both cyto-
plasmic and membrane staining of MUC4 was observed in various
metastatic cases (4D–F).
Transmembrane Mucins Expression in Bladder Pathogenesis
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As seen in Table 4, no significant difference in H-score of
MUC4 staining was observed from grade 2 (0.6660.17) to grade 4
tumors (0.58±0.19).
MUC4 expression in Squamous Cell Carcinoma (SCC)
and adenocarcinoma of the bladder. Of the 51 SCC spots
which were examined (in the TMA), focal positivity was observed
in 38% cases (N= 19, mean H-score 0.06160.009), mild positivity
in 42% cases (N= 21, mean H-score 0.5960.09) and intense
reactivity in 20% cases (N= 10, mean H-score 2.2460.13)
(Fig. 4A). Strong membranous staining was observed in majority
of cells with few cells showing cytoplasmic staining. In MUC4
positive cases, all invasive foci of SCC within the lamina propria
showed uniform staining (Fig. 4A). No significant co-relation
could be assessed between MUC4 expression and grade of
squamous cell carcinoma due to limited information on tumor
grade of cases. Although the number of tissue sections were limited
for adenocarcinoma (N= 8), no or focal MUC4 reactivity was
observed (mean H-score 0.460.22) (Fig. 4B). Similarly, mucinous
adenocarcinomas were also found to negative for MUC4
expression (Fig. 4C).
Expression of MUC1 and MUC4 in Bladder Carcinoma Cell
Lines
After analyzing the expression of mucins in various bladder
pathologies by immunohistochemistry, the expression of MUC1
and MUC4 was analyzed at mRNA and protein levels in different
Figure 2. Expression of MUC1 in various bladder carcinoma phenotypes and metastases. Representative photomicrographs shown for
MUC1 staining in squamous cell carcinoma (A), keratin pearls (B), adenocarcinoma (C) mucinous adenocarcinoma (D), metastasis to bone (E),
metastatic urothelial carcinoma in lymph node (F). Strong membranous expression of MUC1 was observed squamous cell carcinoma (A) and also in
keratin pearls within the squamous cell carcinoma (B). Both mucinous adenocarcinoma (C) and adenocarcinoma showed weak staining (D) for MUC1.
Strong expression of MUC1 was observed in metastatic urothelial carcinoma in bone (E) and lymph node (F). High power view showed that MUC1 is
localized to both cytoplasm and membrane in the metastases (inset of E&F).
doi:10.1371/journal.pone.0092742.g002
Table 2. Variation of MUC1 expression with grades of urothelial carcinoma.
Urothelial Carcinoma
Grade N H-score Intensity
Mean ±SE Median Mean ±SE Median
1 34 0.5160.1a 0.15 2.3760.12 a 2.5
2 70 1.6260.16 b 1.55 2.1960.13 3.0
3 193 1.7060.08 1.6 2.160.078 2
4 21 2.2960.2c 3 2.860.08c 3
Standard error (SE);
acomparison Grade 1 vs. non-neoplastic urothelium (p#0.005);
bp#0.005 vs. Grade 1;
cp,0.05 vs. Grade 3.
doi:10.1371/journal.pone.0092742.t002
Transmembrane Mucins Expression in Bladder Pathogenesis
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bladder carcinoma cell lines (Fig. 5, panel A–C). The panel
included four bladder carcinoma cell lines-T24, TCCSUP,
HT1376 and Scaber. Quantitative RT-PCR for MUC1 and
MUC4 revealed that all the cell lines except T24 expressed MUC1
and MUC4 (Fig. 5A&B). Immunoblotting studies using anti-
MUC1 antibody (HMFG2) and anti-MUC4 antibody (8G7)
indicated differential expression of MUC1 and MUC4 in
TCCSUP, HT1376 and Scaber cell lines (Fig. 5C). No expression
of MUC1 and MUC4 was observed in T24 bladder carcinoma cell
line. Further, different glycoforms of MUC4 were observed in
squamous cell carcinoma cell line in comparison to TCC cell lines.
Overall, mucin MUC1 and MUC4 analyses in bladder cancer
TMA and tissue sections indicated that the expression of MUC1 is
increased while that of MUC4 decreased in UC compared to the
normal non-neoplastic urothelium. Expression of both MUC1 and
MUC4, however, are significantly higher in urothelial carcinoma
metastatic cases compared to localized UC (Fig. 5D).
Discussion
Aberrant expression, localization and glycosylation of mucins
are characteristic events of multiple malignancies (pancreatic,
ovarian, prostate and gastric, lung, and breast). Among various
family members, MUC1 and MUC4 are implicated in tumor
growth, intracellular and extracellular signaling, tumor–stromal
interactions, metastasis, and resistance to chemotherapeutic agents
and in immunity [10,12]. Comprehensive information regarding
expression of these mucins is missing in urothelial carcinoma. The
present study examined the expression of TM mucins MUC1 and
MUC4 in bladder tissue microarray, tissue sections and bladder
carcinoma cell lines. While aberrant changes were observed in
expression and localization pattern of MUC1 between benign and
malignant cases, significant downregulation of MUC4 was
observed during urothelial carcinoma compared to normal and/
or benign bladder tissues.
MUC1 is a membrane-bound O-glycoprotein that is expressed
at the basal level in most epithelial cells [21]. Deregulated
expression of MUC1 is a prominent characteristic of various types
of cancers and inflammatory diseases. Overexpression and
knockdown studies of MUC1, revealed that it leads to increased
tumorigenicity and anti-adhesive properties in number of systems
including cancer cell lines of pancreas, breast, and myeloma, as
well as in MUC1 transgenic model of human breast cancer and
MUC1-transfected 3Y1 rat fibroblasts [12,22–25]. In the present
study, immunohistochemical analyses of MUC1 by HMFG2
antibody revealed that in benign bladder urothelium, MUC1
expression was either restricted to umbrella cells which is observed
in majority of the cases, or it forms a sheath over transitional
epithelium as seen in rare cases. Further, the superficial layer of
bladder urothelium also shows a strong positivity for MUC1
expression in certain cases. Our observation was in accordance
with Simms et al study where presence of MUC1 was observed in
apical layer of transitional epithelium using anti-MUC1 C595
antibody [17]. Further, Patriarca et al also observed the expression
of MUC1 in apical pole of umbrella cells of normal urothelium
[16].
In case of papillary carcinoma, we observed moderate to strong
staining of MUC1 in the apical layer in majority of the tissue
sections. Further, the expression of MUC1 was observed in
luminal as well as in intermediate and basal layers of uroepithe-
Figure 3. Expression of MUC4 in non-neoplastic bladder urothelium, papillary urothelial carcinoma, urothelial carcinoma in situ,
invasive low and high grade urothelial carcinoma. Bladder tumor tissue sections and tissue microarray were probed with anti-MUC4 mAb
(8G7) after non-specific blocking with horse serum. All sections were examined under microscope and the immunoreactivity was evaluated by
reddish brown staining. Representative photomicrographs are shown for MUC4 stained normal non-neoplastic urothelium (A), von Brunn’s nests (B),
non-invasive papillary urothelial carcinoma (C), urothelial carcinoma in situ (D), low (E) and high grade urothelial carcinoma (F). Strong positivity of
MUC4 was observed in various layer bladder urothelium (A). Magnified image shows that distribution of MUC4 is both membranous and cytoplasmic.
Cells in von Brunn’s nest cells showed strong membranous staining of MUC4 (B). Loss of MUC4 expression was observed during non-invasive papillary
carcinoma (C), and carcinoma in situ (D). Both low and high grade urothelial carcinoma showed loss of MUC4 expression (E&F).
doi:10.1371/journal.pone.0092742.g003
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lium. Interestingly, some of the epithelial cells showed much
higher staining for MUC1 in comparison to cells in the vicinity in
some cases of papillary carcinoma. It might account for the
speculation that aberrant changes in MUC1 expression pattern
are due to loss of polarization. In earlier studies, it is suggested that
MUC1 plays a significant role in lumen formation, and has an
inhibitory role in the cell to stromal interaction. From these
studies, it is conceivable that it is a key factor in the detachment of
cells from stroma, allowing for the dissection of the connective
tissue and easing the spread of cell. Elazeez et al observed that
74% of cases of papillary transitional cell carcinoma were positive
for MUC1. Also, the same study demonstrated an increased
expression of MUC1 with increasing grade of papillary carcinoma
i.e. 37.5% of grade 1 cases, 75% of grade 2 cases and 88.9% of
grade 3 cases and this difference in expression was statistically
significant (P,0.01) [15].
In case of urothelial carcinoma, expression of MUC1 showed
varied trend, starting from lack of expression (N= 38 or 12%),
focal reactivity (N=12 or 4%, mean H-score 0.05760.01) to
moderate (N= 147 or 46%, mean H-score 1.0260.05) and intense
immunoreactivity (N= 117 or 37%, mean H-score of 2.8660.02).
The H-score for MUC1 staining increased from grade 1 to grade 2
tumor (Table 3). Further, MUC1 expression was quite high in
66% (8/12) of metastases cases of urothelial carcinoma to various
locations i.e. abdominal wall, back and left frontal lobe of brain
while all the metastases cases from biopsies and resected tissues
(N= 28) were strongly positive for MUC1 expression (mean
intensity 2.7260.45). MUC1 is thought to provide anti-adhesive
properties by counteracting the interactions between adhesion
molecules such as integrin and E-cadherin [26]. Interestingly,
MUC1 overexpression under in vitro conditions has been shown to
reduces adhesion between adjacent cells and between cells and
extracellular matrix (ECM) by mediating binding to some
molecular ligands and blocking binding with other ligands [27].
Similar to these observations, we observed strong expression of
MUC1 towards luminal region of invasive carcinoma cases.
MUC4 is another heavily glycosylated high molecular weight
transmembrane glycoprotein. Despite several studies on the
oncogenic potential of MUC4 in various cancers, there is no
detailed study on the expression of MUC4 in bladder pathology.
Figure 4. Expression of MUC4 in various bladder carcinoma phenotypes and metastases. Representative photomicrographs shown for
MUC4 staining in squamous cell carcinoma (A), adenocarcinoma (B), mucinous adenocarcinoma (C) and metastatic urothelial carcinoma lymph node
(D&E), and metastatic urothelial carcinoma lung (F). Squamous cell carcinoma cases showed moderate expression of MUC4 while MUC4 was found to
be absent in adenocarcinoma. Focal to moderate expression of MUC4 was observed in metastatic urothelial carcinoma to the various organs. High
power view showed that staining pattern is both membranous and cytoplasmic during metastasis.
doi:10.1371/journal.pone.0092742.g004
Table 4. Variation of MUC4 expression with grades of Urothelial Carcinoma.
Urothelial Carcinoma
Grade N H- score Mean Intensity(±SE)
Mean (±SE) Median Mean (±SE) Median
2 33 0.6660.17 0.5 0.6860.18 0.5
3 118 0.5460.07 0.25 0.6860.18 0.5
4 19 0.58±0.19 0.58 0.6160.21 0.6
doi:10.1371/journal.pone.0092742.t004
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In the present study, we examined the expression pattern of
MUC4 in non-neoplastic bladder urothelium and various pheno-
types of malignant bladder. In the non-neoplastic bladder
urothelium, intense staining of MUC4 was observed in all the
layers of urothelium. In contrast to MUC1, staining of MUC4 was
uniform throughout all the layers of urothelium. Interestingly,
intense expression of MUC4 was observed in invaginated
aggregates of urothelial cells known as von Brunn’s nest. In case
of papillary urothelial carcinoma, loss of MUC4 expression was
observed. Analyses of MUC4 in CIS cases revealed the loss of
MUC4 mucin during tumorprogression. Further MUC4 expres-
sion was either absent or present focally in low grade and high
grade invasive carcinoma cases from tissues. Additionally during
the study, low expression of MUC4 in comparison to non-
neoplastic bladder urothelium was observed in SCC and
adenocarcinoma. Since the loss of MUC4 expression was observed
in non-invasive papillary UC and urothelial CIS cases, the present
study suggests that loss of MUC4 might be one of the early events
during development of urothelial carcinoma. Similar to our study,
Singh et al observed the loss of MUC4 during development of
prostate cancer [7]. During the study, they observed that the
expression level of MUC4 was much lower in prostatic adenocar-
cinoma tissue (CaP) compared to adjacent normal/benign prostate
tissue (N/BPH). Treatment of prostate cancer cell lines with
inhibitor of histone deacetylases and DNA methyl transferases lead
to increased expression of MUC4. Singh et al, suggested the
epigenetic mechanism might be regulating the MUC4 expression
during pathogenesis of prostate cancer. Further studies need to be
carried out in urothelial carcinoma to decipher the mechanism of
MUC4 downregulation. In summary, intense expression of
MUC4 was observed in normal epithelium and its progressive
loss in carcinoma in situ/papillary carcinoma stage which was
followed by complete loss during high and low grade invasive
carcinoma (Fig. 5D). In our study, in limited cases, we observed
that expression of MUC4 comes back during metastasis, however
further studies are warranted to confirm this observation.
Conclusions
In conclusion, our findings suggest that both the pattern and
level of mucin expression is significantly associated with the type of
urothelial carcinoma. With regard to MUC1, aberrant changes
were observed both in expression and localization pattern while
significant loss of MUC4 expression was observed with progression
of UC. Since the loss of MUC4 expression is observed at very early
stages, our study indicates that MUC4 loss might be of diagnostic
relevance for early detection of urothelial carcinoma. Further in
Figure 5. Expression analysis of transmembrane mucins MUC1 and MUC4 at RNA and protein level in various bladder carcinoma
cell lines and tabular representation of mucin expression as observed during tissue staining in the urothelial carcinoma
progression. Quantitative RT-PCR analyses of MUC1 (A) and MUC4 (B) showed that all bladder carcinoma cell line except T24 expresses MUC1 and
MUC4. Highest expression of both MUC1 and MUC4 was observed in tumor cell line HT1376. For expression analyses of mucin MUC1 and MUC4 at
protein level, the protein lysates from all the bladder carcinoma cell lines were resolved on 2% agarose gel and probed with anti-MUC1 (HMFG2) and
anti-MUC4 (8G7) antibodies (Panel C). b-actin resolved on 10% SDS-PAGE was used as a loading control (Panel C). No expression of any mucin MUC1
and MUC4 was observed in T24 while other cell lines expressed both the mucins. (D) Tabular representations of MUC1 and MUC4 expression during
bladder carcinoma progression. Significant changes in expression of both MUC1 and MUC4 were observed during progression of urothelial
carcinoma. Progressive increase in MUC1 expression was observed through various stages and grades of bladder cancer whereas the expression of
MUC4 declined with disease progression. In a subset of metastatic cases of urothelial carcinoma, the expression of MUC4 was detected.
doi:10.1371/journal.pone.0092742.g005
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metastatic cases, we observed revival of MUC4 expression.
Immunohistochemistry for MUC4 may be a useful adjunct to
morphological assessment of difficult cases in distinguishing
urothelial CIS/carcinoma from its benign mimics. Further studies
are warranted to decipher the molecular mechanism and effect of
MUC4 loss on development of bladder carcinoma.
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